University of Missouri

The Governors of the University of Alberta

Kattesh V Katti

Wynn A Volkert

Kavita K Katti

Alan R Ketring

Raghuraman Kannan

Douglas E Berning

Satish Kumar Nune

Prahlad R Singh

Stan Casteel

Cathy Sue Cutler

Kannan Raghuraman

Nripen Chanda

Hariprasad Gali

Ravi Shukla

Robert Churchill

Menka Khoobchandani

C Jeffrey Smith

Srinivasa Rao Karra

Ronald G Cavell

Ajit Zambre

Timothy J Hoffman

Anandhi Upendran

Charles W Caldwell, Jr

Vinay Mutalik

V Sreenivasa Reddy

Nagavara Kishore Pillarsetty

Kandikere R Prabhu

Chintamani Joshi

Alsam Khan

Vijaya Kattumuri

Evan Boote

Kativa K Katti

Menka Khhobchandani

Ayurvedic encapsulated gold nanoparticles, methods of fabrication and methods of treatment are provided. A method of fabrication includes mixing dried gooseberry product or mango peel product or phytochemical existent therein, into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts proceeds, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible Ayurvedic encapsulated gold nanoparticles. An Ayurvedic medicine consists of a non-radioactive gold nanoparticle encapsulated with phytochemical existent in mango peal or gooseberry in a capsule with curcumin extract and gum Arabic.

Ayurvedic encapsulated gold nanoparticles, fabrication methods and cancer therapeutic methods

A method for forming encapsulated gold nanoparticles mixes mangiferin into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts is permitted, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible gold nanoparticles coated with mangiferin. The gold salts can consist of AuCl4, or can consist of radioactive gold salts. A cancer therapy method injects a solution of mangiferin encapsulated gold nanoparticles directly into a solid tumor. A solution consisting of an aqueous or alcoholic medium and mangiferin encapsulated gold nanoparticles is provided. The mangiferin encapsulated gold nanoparticles can have core sizes of &#x2dc;5-20 nm and total sizes of &#x2dc;20-120 nm.

Mangiferin encapsulated gold nanoparticles, fabrication methods and cancer therapeutic methods

The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from soy or lentil plant material or a reactive extract thereof of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. The nanoparticles can be introduced in vivo to conduct enhanced imaging. The nanoparticles can also be introduced in vivo to conduct therapy.

Soy, lentil or extract stabilized, biocompatible gold nanoparticles

A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal comprises functionalized gold nanoparticles configured to be directed to one or more of a target organ, tissue and lesion of the mammal.

Stabilized gold nanoparticle and contrast agent

The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from epigallocatechin Gallate (EGCg), which is a polyphenols- or flavonoids-rich plant material that can be obtained from green tea. The EGCg is an antioxidant reducing agent derived from green tea. The gold nanoparticles of the invention can be radioactive or non radioactive and are formed via a simple room temperature fabrication method. In preferred embodiment method of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with EGCg in a buffer, such as deionized water. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a coating of EGCg. The thermodynamically feasible redox couple of AuCl4-/EGCg leading to the reduction of AuCl4- by EGCg to form gold nanoparticles. In another embodiment, pre-cooled gold salt and EGCg solutions form multi-layered EGCg coated particles.

EGCG stabilized gold nanoparticles and method for making same

The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In preferred embodiments, the coating consists of material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material.

Stabilized, biocompatible gold nanoparticles

The present invention provides compounds, pharmaceutical compositions, and methods that can be used to treat pathologies that are due to copper overload or to the presence of reactive oxygen species.

Compounds for treatment of copper overload

The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In methods of the invention, an aqueous solution containing gold salts is mixed with polyphenols- or flavanoids-rich plant material. In preferred embodiment methods of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with black tea, turmeric, curcumin or cinnamon or a similar naturally occurring polyphenols- or flavanoids-rich plant material. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a coating of the polyphenols- or flavanoids-rich plant material. The black tea, turmeric, curcumin or cinnamon or similar naturally occurring polyphenols- or flavanoids-rich plant material can be a powder or can be in its root or bark form.

Stabilized, biocompatible gold nanoparticles and enviro-friendly method for making same

There is provided a complex for use as a therapeutic pharmaceutical, the complex has a ligand containing at least one hydroxyalkyl phosphine donor group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of treating cancer by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of preventing the metastasis of cancer and arresting cell growth by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex.

Gold-containing chemotherapeutic agents

This invention describes a novel strategy to produce phosphine-functionalized biomolecules (e.g. peptides or proteins) for potential use in the design and development of site-specific radiopharmaceuticals for diagnosis or therapy of specific cancers. Hydrophilic alkyl phosphines, in general, tend to be oxidatively unstable. Therefore, incorporation of such phosphine functionalities on peptide (and other biomolecule) backbones, without oxidizing the P centers, is difficult. In this context this discovery reports on a new technology by which phosphines, in the form of bifunctional chelating agents, can be directly incorporated on biomolecular backbones using manual synthetic or solid phase peptide synthesis methodologies. The superior ligating abilities of phosphine ligands, with various diagnostically (e.g. TC-99m) or therapeutically (e.g. Re186/188, Rh-105, Au-199) useful radiometals, coupled with the findings that the resulting complexes demonstrate high in vivo stability makes this approach useful in the development of radiolabeled biomolecules for applications in the design of tumor-specific radiopharmaceuticals.

Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents

There is provided a method of labeling a biomolecule with a transition metal or radiometal in a site specific manner to produce a diagnostic or therapeutic pharmaceutical compound by synthesizing a P N -bifunctional chelating agent intermediate, complexing the intermediate with a radio metal or a transition metal, and covalently linking the resulting metal-complexed bifunctional chelating agent with a biomolecule in a site specific manner. Also provided is a method of synthesizing the &mdash;PR containing biomolecules by synthesizing a P N -bifunctional chelating agent intermediate, complexing the intermediate with a radiometal or a transition metal, and covalently linking the resulting radio metal-complexed bifunctional chelating agent with a biomolecule in a site specific manner. There is provided a therapeutic or diagnostic agent comprising a &mdash;PR containing biomolecule.

Bifunctional chelating agent for the design and development of site specific radiopharmaceuticals and biomolecule conjugation strategy

A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises at least one functionalized hydroxyalkyl phosphine donor group and one or more sulfur or nitrogen donor and a metal combined with the ligand.

Hydroxymethyl phosphine compounds for use as diagnostic and therapeutic

A method of forming phosphine-amine conjugates includes reacting a hydroxymethyl phosphine group of an amine-free first molecule with at least one free amine group of a second molecule to covalently bond the first molecule with the second molecule through an aminomethyl phosphorus linkage and the conjugates formed thereby.

Conjugate and method for forming aminomethyl phosphorus conjugates

A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises a functionalized hydroxyalkyl phosphine ligand and a metal combined with the ligand.

Growing community of inventors

Columbia, MO, United States of America

Kattesh V Katti